Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents

NCT01502904 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Stable Angina or Acute Coronary Syndrome Considered for Percutaneous Coronary Intervention With Dyslipidemia or Hypertension

Interventions

DEVICE: Sirolimus-eluting stent
DEVICE: Biolimus-eluting stents
DRUG: pravastatin 20mg/day after DES implantation
DRUG: pitavastatin 2mg/day after DES implantation
DRUG: Non-ARB /day after DES implantation
DRUG: Eposartan 600mg/day after DES implantation

Sponsor

Yonsei University